Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2025 | LEGEND: Phase II trial of detalimogene voraplasmid in NMBIC

Felix Guerrero-Ramos • 28 Mar 2025
EAU 2025
Bladder Cancer Genitourinary Cancer Detalimogene voraplasmid
LEGEND

Félix Guerrero-Ramos, MD, PhD, Hospital Universitario 12 de Octubre in Madrid, Spain, discusses the Phase II portion of the LEGEND trial (NCT04752722), evaluating detalimogene voraplasmid, an intravesical, non-viral gene therapy for patients with high-risk, bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer (NMBIC). Following promising safety and efficacy data in Phase I, the current study assesses complete response at 48 weeks, alongside progression-free survival, response durability, and quality of life. This interview took place at the 2025 European Association of Urology (EAU) Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Felix Guerrero-Ramos

Individualizing therapy beyond early cystectomy in high-risk NMIBC
0:57
Individualizing therapy beyond early cystectomy in high-risk NMIBC
Felix Guerrero-Ramos • 26 Feb 2026
Selecting patients with high-risk NMIBC for BCG-immunotherapy strategies
1:28
Selecting patients with high-risk NMIBC for BCG-immunotherapy strategies
Felix Guerrero-Ramos • 26 Feb 2026
Evolving management of high-risk BCG-unresponsive NMIBC
0:53
Evolving management of high-risk BCG-unresponsive NMIBC
Felix Guerrero-Ramos • 26 Feb 2026
CREST: exploratory analysis of sasanlimab and BCG in very high-risk NMIBC
0:49
CREST: exploratory analysis of sasanlimab and BCG in very high-risk NMIBC
Felix Guerrero-Ramos • 26 Feb 2026

Related Videos

Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
2:19
Smoking-associated genomic alterations linked to poorer outcomes in metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
The content of VJOncology is intended for healthcare professionals